Войти на сайт

Комментарий: Риск развития внутричерепного кровоизлияния при использовании антагонистов протеаз-активируемого рецептора-1


Комментарий Г.Дж. Фалконе и соавт.

Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA; Hemorrhagic Stroke Research Group, Massachusetts General Hospital, Boston, MA; Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Massachusetts General Hospital, Boston MA; and Program in Medical and Population Genetics, Broad Institute, Cambridge MA.
Ключевые слова: внутричерепное кровоизлияние, антитромбоцитарные препараты, антитромбоцитарные соединения

Подписка


Литература


  1. World Health Organization (WHO). World Health Statistics 2012. Geneva, Switzerland: World Health Organization (WHO); 2012.
  2. Leon D.A. Trends in European life expectancy: a salutary view. Int J Epidemiol. 2011;40:271–277.
  3. Davм G., Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482–2494.
  4. Meadows T.A., Bhatt D.L. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res. 2007;100:1261–1275.
  5. Fintel D.J. Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. Vasc Health Risk Manag. 2012;8:77–89.
  6. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.
  7. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.
  8. Chintala M., Strony J., Yang B., Kurowski S., Li Q. SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys. Arterioscler Thromb Vasc Biol. 2010;30:2143–2149.
  9. Becker R.C., Moliterno D.J., Jennings L.K., Pieper K.S., Pei J., Niederman A., et al. TRA-PCI Investigators. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet. 2009;373:919–928.
  10. Goto S., Yamaguchi T., Ikeda Y., Kato K., Yamaguchi H., Jensen P. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb. 2010;17:156–164.
  11. Tricoci P., Huang Z., Held C., Moliterno D.J., Armstrong P.W., Van de Werf F., et al. TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366:20–33.
  12. Morrow D.A., Braunwald E., Bonaca M.P., Ameriso S.F., Dalby A.J., Fish M.P., et al. TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366:1404–1413.
  13. Chatterjee S., Sharma A., Mukherjee D. PAR-1 antagonists: current state of evidence. J Thromb Thrombolysis. Published ahead of print May 29, 2012.
  14. Capodanno D., Bhatt D.L., Goto S., O’Donoghue M.L., Moliterno D.J., Tamburino C., et al. Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials. J Thromb Haemost. 2012;10:2006–2015.
  15. Moher D., Liberati A., Tetzlaff J., Altman D.G. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–269, W64.
  16. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan DJ., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.
  17. Qureshi A.I., Mendelow A.D., Hanley D.F. Intracerebral haemorrhage. Lancet. 2009;373:1632–1644.
  18. Biffi A., Sonni A., Anderson C.D., Kissela B., Jagiella J.M., Schmidt H., et al; International Stroke Genetics Consortium. Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol. 2010;68:934–943.
  19. Falcone G.J., Biffi A., Devan W.J., Jagiella J.M., Schmidt H., Kissela B., et al. Burden of risk alleles for hypertension increases risk of intracerebral hemorrhage. Stroke. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22933587. Accessed October 1, 2012.
  20. van Asch C.J., Luitse M.J., Rinkel G.J., van der Tweel I., Algra A., Klijn C.J. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9:167–176.
  21. Fisher C.M. Lacunar strokes and infarcts: a review. Neurology. 1982;32:871–876.
  22. Vinters H.V. Cerebral amyloid angiopathy. A critical review. Stroke. 1987;18:311–324.


Похожие статьи

К содержанию номера

Бионика Медиа